Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seer Inc Cl A
(NQ:
SEER
)
2.020
+0.120 (+6.32%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seer Inc Cl A
< Previous
1
2
Next >
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
October 31, 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite
From
Seer, Inc.
Via
GlobeNewswire
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
October 21, 2024
Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional...
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
October 17, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Appoints Nicolas Roelofs to its Board of Directors
August 14, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 09, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports Second Quarter 2024 Financial Results
August 08, 2024
Launched STAC in Europe and additional customer papers published in leading journals
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
June 11, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
June 02, 2024
Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports First Quarter 2024 Financial Results
May 08, 2024
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications
From
Seer, Inc.
Via
GlobeNewswire
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
May 08, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
April 23, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
February 29, 2024
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
February 21, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
February 06, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
February 01, 2024
From
Seer, Inc.
Via
GlobeNewswire
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
December 21, 2023
From
Seer, Inc.
Via
GlobeNewswire
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
November 10, 2023
From
Seer, Inc.
Via
GlobeNewswire
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
November 08, 2023
Seer technology receives recognition for excellence in the field of proteomics
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports Third Quarter 2023 Financial Results
November 07, 2023
Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence
From
Seer, Inc.
Via
GlobeNewswire
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
November 01, 2023
Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
October 19, 2023
From
Seer, Inc.
Via
GlobeNewswire
Seer to Participate in Upcoming September Investor Conferences
September 08, 2023
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports Second Quarter 2023 Financial Results
August 08, 2023
Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies
From
Seer, Inc.
Via
GlobeNewswire
Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference
July 27, 2023
From
Seer, Inc.
Via
GlobeNewswire
Seer to Report Second Quarter 2023 Financial Results on August 8, 2023
July 13, 2023
From
Seer, Inc.
Via
GlobeNewswire
Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center
June 07, 2023
Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific...
From
Seer, Inc.
Via
GlobeNewswire
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
June 01, 2023
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale
From
Seer, Inc.
Via
GlobeNewswire
Seer Reports First Quarter 2023 Financial Results
May 09, 2023
From
Seer, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.